Compare AbbVie Inc (ABBV) vs VNET Group Inc (VNET) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

VNET trades at $7.81, down 1.39% today, amid bearish technical signals and recent earnings misses. The stock shows negative profitability with a -21.63% net income margin and -43.21% ROE for 2025, though revenue reached $9.95B. Analyst sentiment remains positive with 62.5% buy ratings, pointing to a 54% upside target. Recent news highlights strategic AI investments and leadership changes, while a class action settlement adds legal overhang.

The outlook is mixed: strong revenue growth and AI demand offer upside, but persistent losses and high debt pose risks. Investors should weigh analyst optimism against fundamental weaknesses and legal uncertainties before considering a position.